Medical Device Industry News

U.S. Patent Office denies Medtronic request in Endotach stent case

October 22, 2014 by Val Kennedy

The U.S. Patent & Trademark Office denies Medtronic's request for inter partes review of a disputed patent in its ongoing case against Endotach.

U.S. Patent Office denies Medtronic request in Endotach stent case

MassDevice.com +3 | The top 3 medtech stories for October 22, 2014

October 22, 2014 by MassDevice

Plus 3

Say hello to MassDevice +3, a bite-sized view of the top three medtech stories of the day. This feature of MassDevice.com's coverage highlights our 3 biggest and most influential stories from the day's news to make sure you're up to date on the headlines that continue to shape the medical device industry.

 

Sorin drops $20m on stake in Respicardia

October 22, 2014 by Alexander Soule

Sorin Group drops $20 million on a stake in Minnetonka, Minn.-based Respicardia, which is developing implantable devices to treat central sleep apnea.

Sorin drops $20m on stake in Respicardia

Sorin Group (BIT:SRN) said it invested $20 million in a minority stake and controlling option in Minnetonka, Minn.-based Respicardia, which is developing implantable devices to treat central sleep apnea.

EQT frontrunner for Siemens hearing-aids business: sources

October 22, 2014 by MassDevice

Siemens is in advanced talks to sell its hearing-aids business to private equity shop EQT, unnamed sources tell Reuters.

EQT frontrunner for Siemens hearing-aids business: sources

Jury deliberations begin in first trial over DePuy's Pinnacle hips

October 22, 2014 by MassDevice

A jury begins deliberations in the 1st trial over DePuy Orthopaedics' Pinnacle metal-on-metal hip implant.

Jury deliberations begin in first trial over DePuy's Pinnacle hips

Covidien, Medtronic shares jump on affirmation of $43B merger

October 22, 2014 by Brad Perriello

Shares of Medtronic and Covidien gain after Medtronic affirms its $43 billion acquisition plans, saying it now expects to close the deal for Covidien late this year or early in 2015.

Covidien, Medtronic shares jump on affirmation of $43B merger

Abbott to go ahead with $5.3B Mylan deal, says 3rd-quarter sales match forecasts

October 22, 2014 by MassDevice

Abbott says it will go ahead with its plan to deal its generic pharmaceuticals line to Mylan for $5.3 billion and reports 3rd-quarter sales in line with expectations.

Abbott to go ahead with $5.3B Mylan deal, says 3rd-quarter sales match forecasts
Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp